<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03511378</url>
  </required_header>
  <id_info>
    <org_study_id>LRP/PegGCSF/2016/004</org_study_id>
    <nct_id>NCT03511378</nct_id>
  </id_info>
  <brief_title>Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer</brief_title>
  <official_title>An Open-label, Randomized, Comparative, Parallel Group Study to Assess the Immunogenicity of Lupin's Peg-filgrastim Versus Neulasta® as an Adjunct to Chemotherapy in Patients With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lupin Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lupin Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the immunogenicity of Peg-filgrastim versus Neulasta®
      as an adjunct to chemotherapy in patients with breast cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, randomized, comparative, parallel group study to assess the Immunogenicity of
      Lupin's Peg-filgrastim versus Neulasta® as an Adjunct to Chemotherapy in Patients with Breast
      Cancer

      Primary Objective: To assess the immunogenicity of Lupin's Peg-filgrastim with Neulasta® in
      patients with breast cancer.

      Secondary Objectives: To assess the safety of Lupin's Peg-filgrastim with Neulasta® in
      patients with breast cancer
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 6, 2018</start_date>
  <completion_date type="Actual">January 9, 2019</completion_date>
  <primary_completion_date type="Actual">January 9, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Immunogenicity Endpoint: Comparison of cumulative Incidence of anti-pegfilgrastim antibodies (binding &amp; neutralizing) at the end of cycle 4 (Day 84)</measure>
    <time_frame>End of cycle 4, Day 84</time_frame>
    <description>The difference in the proportion of patients with cumulative incidence of anti-pegfilgrastim antibodies (binding &amp; neutralizing) to Pegfilgrastim between study groups at the end of cycle 4 (Day 84) will be calculated. Those samples confirmed to be positive for binding antibodies will be analyzed for presence of neutralizing antibodies to Pegfilgrastim.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Immunogenicity endpoint: Comparison of cumulative incidence of anti-peg antibodies (binding &amp; neutralizing) between treatment groups at the end of cycle 4 (Day 84)</measure>
    <time_frame>Day 84.</time_frame>
    <description>Presence of anti-pegfilgrastim antibodies between treatment group at the end of cycle 4 (Day 84)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Immunogenicity endpoint: Comparison of incidence of anti-pegfilgrastim antibodies (binding &amp; neutralizing) to Pegfilgrastim between treatment groups on Day 10, Day 21, Day 42, Day 63 and Day 84</measure>
    <time_frame>Day 10, 21, 42, 63, and Day 84</time_frame>
    <description>comparison of incidence of anti-peg antibodies (binding &amp; neutralizing) to pegfilgrastim between treatment groups on Day 10, Day 21, Day 42, Day 63, Day 84</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Immunogenicity Endpoint:</measure>
    <time_frame>Day 10, Day 21, Day 42, Day 63 and Day 84.</time_frame>
    <description>Comparison of incidence of anti-peg antibodies (binding &amp; neutralizing) between treatment groups on Day 10, Day 21, Day 42, Day 63 and Day 84</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Lupin's Pegfilgrastim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg, subcutaneous injection on day 2/3 of each 21 ± 3 day cycle. Number of cycles: 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neulasta®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg, subcutaneous injection on day 2/3 of each 21 ± 3 day cycle. Number of cycles: 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lupin's Pegfilgrastim</intervention_name>
    <description>Administration of Pegfilgrastim</description>
    <arm_group_label>Lupin's Pegfilgrastim</arm_group_label>
    <other_name>INvestigational product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neulasta®</intervention_name>
    <description>Administration of Neulasta®</description>
    <arm_group_label>Neulasta®</arm_group_label>
    <other_name>Reference</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must be able and willing to give written informed consent prior to any study
             related procedures

          2. Ambulatory, female patients with an age ≥ 18 years

          3. Patients with histologically or cytologically proven diagnosis of breast cancer who
             are eligible for neoadjuvant or adjuvant chemotherapy.

          4. Patients who are planned and eligible to receive/ receiving myelosuppressive
             chemotherapy regimen that contains at least one chemotherapeutic agent from docetaxel/
             paclitaxel / doxorubicin/ cyclophosphamide/ epirubicin

          5. Patients who have not received any hematopoietic growth factors (e.g. G-CSF, PegGCSF,
             erythropoietin) or cytokines (e.g. interleukins, interferons) anytime in the past

          6. Patients with baseline WBC ≥ LLN/ 3.5 x 109/L, ANC of ≥ 1.5 x 109/L, platelet count ≥
             100 x 109/L and hemoglobin ≥ 8.5 g/dL

          7. Patients with ECOG Performance status of ≤ 2

          8. Patient who have estimated life expectancy of more than six months

          9. No evidences of hemorrhage

        Exclusion Criteria:

        1 Male patients

        2. Hypersensitivity to any of the study drugs or its components like E.coli proteins or
        similar product

        3. Patients weighing &lt;45 Kg

        4. Patients with myeloid malignancies and myelodysplasia or evidence of metastatic disease
        in bone marrow or brain

        5. Patients currently receiving radiation therapy or have completed radiation therapy
        within 4 weeks before study entry or likely to receive radiotherapy during the study

        6. Patients with prior bone marrow or stem cell transplantation

        7. Patients with chronic use of oral corticosteroids (Except ≤ 20 mg/day dose of
        prednisolone/ equivalent steroids), immunotherapy, monoclonal antibody therapy and/or
        biological therapy or use of any other pegylated drug.

        8. Patients with history of systemic antibiotic use within 72 hours prior to chemotherapy

        9. Patients with any active infection which may require systemic antimicrobial therapy.
        Patients with inadequate hepatic and renal function [defined as Alkaline Phosphatase &gt; 2.5
        X Upper limits of normal (ULN), serum SGOT &gt; 2.5 X ULN, SGPT &gt; 2.5 X ULN, Total bilirubin &gt;
        1.5 X ULN and Creatinine &gt; 1.5 X ULN of the reference range at the screening assessment]

        10. Patients with seropositivity for HIV or HBV or HCV

        11. Known cases of Sickle Cell Anemia

        12. Patients with radiographic evidence of active pulmonary infections and/or recent
        history of pneumonia within 1 month of screening

        13. Patients with clinically evident splenomegaly confirmed subsequently by ultrasonography

        14. Patients with any other clinically significant disease(s) which, in the opinion of the
        investigator, could compromise the patient's involvement in the study or overall
        interpretation of the data. [for e.g. uncontrolled hematologic, renal, hepatic, endocrine,
        neurologic, psychiatric, metabolic, pulmonary, cardiovascular disease/impaired functioning
        or history of any autoimmune disease]

        15. Patients who have participated in another therapeutic clinical study within the past 30
        days prior to screening, or are likely to simultaneously participate in another therapeutic
        clinical study

        16. Patients who are doubtful to comply with study procedures for mental, psychological or
        social reasons.

        17. Women of child-bearing potential who are not willing to follow a reliable &amp; effective
        contraceptive measure during the course of the study &amp; at least 3 months after the last
        dose of study drug.

        18. Pregnant and Breast feeding women.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dhananjay Bakhle, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lupin Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M S Patel Cancer Centre,</name>
      <address>
        <city>Gokal</city>
        <state>Anand</state>
        <zip>388325</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Cancer Center</name>
      <address>
        <city>Vijayawada</city>
        <state>Andhra Pradesh</state>
        <zip>520002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research &amp; Development Department, HCG Cancer Center</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apple Hospital</name>
      <address>
        <city>Sūrat</city>
        <state>Gujarat</state>
        <zip>395002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nirmal Hospital</name>
      <address>
        <city>Sūrat</city>
        <state>Gujarat</state>
        <zip>395002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shree Himalaya Cancer Hospital &amp; Research Institute,</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>390007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kailash Cancer Hospital &amp; Research Center</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>391760</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adhar health Institute</name>
      <address>
        <city>Hisar</city>
        <state>Haryana</state>
        <zip>125001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sri Venketeshwara Hospital, Dept of Medical oncology</name>
      <address>
        <city>Bengaluru</city>
        <state>Karnataka</state>
        <zip>560068</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Curie Manavata Cancer Centre</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>Nasik- 422004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Government Medical College &amp; Hospital</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Hospital</name>
      <address>
        <city>Nigdi</city>
        <state>Maharashtra</state>
        <zip>411044</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bhaktivedanta Hospital &amp; Research Institute</name>
      <address>
        <city>Thāne</city>
        <state>Maharashtra</state>
        <zip>401107</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Department</name>
      <address>
        <city>Bande</city>
        <state>Nagpur</state>
        <zip>44026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acharya Tulsi Regional Cancer Treatment &amp; Research Institute</name>
      <address>
        <city>Bīkaner</city>
        <state>Rajahstan</state>
        <zip>334003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Clinical Research Services Pvt Ltd.</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>500004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Gleneagles Hospitals</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>7000054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 20, 2018</study_first_submitted>
  <study_first_submitted_qc>April 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2018</study_first_posted>
  <last_update_submitted>October 4, 2019</last_update_submitted>
  <last_update_submitted_qc>October 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Carcinoma</keyword>
  <keyword>Breast neoplasms</keyword>
  <keyword>Breast Tumors</keyword>
  <keyword>Cancer of Breast</keyword>
  <keyword>Anti-Drug Antibodies (ADA)</keyword>
  <keyword>Immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

